Nexstim

The leader in navigated stimulation of the brain

Nexstim develops and markets navigated brain stimulation "NBS" devices for use in diagnostics (neurosurgery) and therapy. Headquartered in Helsinki, Finland, Nexstim employs a staff with remarkable experience in neurophysiology and brain research, extensive knowledge of modern healthcare technology as well as enthusiasm for continuous improvement.
Established in 2000, Nexstim launched its first commercial product in 2003. Today there are NBS products in more than a hundred of the world´s leading hospitals and brain research centers. The NBS System has been particularly well received in Germany, where nine of the most advanced neurosurgery departments are using NBS for surgical planning.

Navigated brain stimulation is clinical application of TMS in brain diagnostics and therapy, using the patient's MRI to navigate the electrical field induced in the brain by the TMS coil. TMS stands for transcranial magnetic stimulation, whereby harmless, magnetic waves are used to excite neurons in the upper cortical layers of the brain. TMS has been studied for over 25 years and the method is well understood to be safe.

Navigated brain stimulation in neurosurgical planning

The NBS System is CE-marked and has been cleared by the U.S. FDA for functional mapping of the motor and speech cortices prior to neurosurgery in patients with a diagnosis of tumor or epilepsy. Using NBS can enable more patients to be offered a surgical option and the information NBS provides may lower risk of damage to eloquent cortex due to neurosurgery. Reimbursement codes for NBS mapping are available in Germany and USA.

Navigated brain therapy

In 2012, Nexstim launched a novel navigated brain therapy (NBT®) device for the treatment of brain injury and disease using repetitive TMS (rTMS) guided by a patient´s own MRI-scan. NBT is initially being studied in clinical research for the treatment of patients suffering the consequences of chronic stroke. Initial results are showing great promise in helping stroke patients regaining lost motor control. NBT® also enables personalized non-drug treatment for people suffering from major depressive disorder (clinical depression). The NBT® System meets the requirements of the European Medical Devices Directive (MDD) and is CE-marked.




Siirry sivun alkuun
 © Nexstim Oy
Legal notices | Privacy | Sitemap
Note to U.S. residents: The NBS System and NexSpeech® are cleared by the FDA for use in pre-surgical planning for patients undergoing brain surgery. See Indications for use.